IND

Molecular Templates, Inc. to Present Interim Results on MT-5111 at the 45th Annual San Antonio Breast Cancer Symposium (SABCS) and Participate at the 64th American Society of Hematology (ASH) Annual Meeting

Retrieved on: 
Friday, December 2, 2022

Molecular Templates will also participate in one-on-one meetings at the 64th American Society of Hematology (ASH) Annual Meeting which will take place December 10 December 13, 2022 at the Ernest N. Morial Convention Center in New Orleans, LA.

Key Points: 
  • Molecular Templates will also participate in one-on-one meetings at the 64th American Society of Hematology (ASH) Annual Meeting which will take place December 10 December 13, 2022 at the Ernest N. Morial Convention Center in New Orleans, LA.
  • In-person and virtual meetings may be scheduled directly with Molecular Templates.
  • Forward-looking statements are not guarantees of future performance and involve risks and uncertainties.
  • Any forward-looking statements contained in this press release speak only as of the date hereof, and Molecular Templates specifically disclaims any obligation to update any forward-looking statement, whether because of new information, future events or otherwise.

BetterLife To Present BETR-001 Preclinical Data at the 61ST Annual Meeting of the American College of Neuropsychopharmacology (ACNP) in Phoenix, Arizona

Retrieved on: 
Friday, December 2, 2022

Dr. Aguilar-Valles will present preclinical data supporting the acute and long-term anti-depressant activity of BETR-001 monotherapy in animal models.

Key Points: 
  • Dr. Aguilar-Valles will present preclinical data supporting the acute and long-term anti-depressant activity of BETR-001 monotherapy in animal models.
  • Furthermore, the data shows that BETR-001 promotes structural neuroplasticity in brain neurons and this effect is partly mediated by the activation of 5-HT2A receptor.
  • BetterLife also owns a drug candidate for the treatment of viral infections such as COVID-19 and other respiratory viral infections.
  • The department has an interdisciplinary approach to understanding the emergence, prevention and treatment of mental and physical disorders.

Beam Therapeutics Announces FDA Has Lifted the Clinical Hold on the Investigational New Drug Application for BEAM-201

Retrieved on: 
Friday, December 2, 2022

BEAM-201 is a potent and specific anti-CD7, multiplex-edited, allogeneic chimeric antigen receptor T-cell development candidate.

Key Points: 
  • BEAM-201 is a potent and specific anti-CD7, multiplex-edited, allogeneic chimeric antigen receptor T-cell development candidate.
  • We believe the future of cell therapy involves high levels of cell engineering, enabled by multiplex base editing technology.
  • Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines.
  • This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.

Bio-Thera Solutions Announces BAT8006 (Folate-Receptor-α-ADC) and BAT8008 (Trop2-ADC) Poster Presentations at the 2022 San Antonio Breast Cancer Symposium

Retrieved on: 
Friday, December 2, 2022

Bio-Thera Solutions, a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and a pipeline of biosimilars, today announced the company will present two posters at the 2022 San Antonio Breast Cancer Symposium (SABCS) taking place December 6 - 10, 2022 in San Antonio, Texas.

Key Points: 
  • Bio-Thera Solutions, a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and a pipeline of biosimilars, today announced the company will present two posters at the 2022 San Antonio Breast Cancer Symposium (SABCS) taking place December 6 - 10, 2022 in San Antonio, Texas.
  • Folate Receptor is a naturally occurring receptor that is overexpressed in many types of cancer, including breast cancer and ovarian cancer.
  • Trop-2 is a naturally occurring receptor that is overexpressed in many types of cancer, including triple negative breast cancer and gastric cancer.
  • This news release contains certain forward-looking statements relating to BAT8006, BAT8008 or the product pipelines in general of Bio-Thera Solutions.

Bio-Thera Solutions Announces Presentation of BAT8009 (B7-H3-ADC) at the 2nd Annual ADC Target Selection Summit

Retrieved on: 
Friday, December 2, 2022

Other new ADC assets developed using this next-gen ADC platform include BAT8006 (Folate-Receptor-alpha-ADC), BAT8007 (Nectin4-ADC), BAT8008 (Trop2-ADC) and BAT8010 (Her2-ADC).

Key Points: 
  • Other new ADC assets developed using this next-gen ADC platform include BAT8006 (Folate-Receptor-alpha-ADC), BAT8007 (Nectin4-ADC), BAT8008 (Trop2-ADC) and BAT8010 (Her2-ADC).
  • All of these ADC assets are currently in, or about to begin, Phase 1 clinical trials.
  • BAT8009 is being developed for use as a single agent and in combination with other agents for the treatment of multiple cancers.
  • This news release contains certain forward-looking statements relating to BAT8009 or the product pipelines in general of Bio-Thera Solutions.

Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Thursday, December 1, 2022

The award was made on December 1, 2022 under Oncternals 2021 Employment Inducement Incentive Award Plan, which provides for the granting of equity awards to new employees of Oncternal as an inducement to join the Company.

Key Points: 
  • The award was made on December 1, 2022 under Oncternals 2021 Employment Inducement Incentive Award Plan, which provides for the granting of equity awards to new employees of Oncternal as an inducement to join the Company.
  • The award consists of an option to purchase 77,400 shares of Oncternal common stock.
  • The option has a 10-year term and an exercise price equal to the closing price of Oncternals common stock on the date of grant.
  • The award was approved by Oncternals compensation committee, comprised entirely of independent directors, as required by Nasdaq Rule 5635(c)(4), and was granted as an inducement material to the employee entering into employment with Oncternal in accordance with Nasdaq Rule 5635(c)(4).

VirTech Bio presenting at the Florida Venture Summit Dec. 6, 2022

Retrieved on: 
Thursday, December 1, 2022

Dr. Hack became CEO of VirTech Bio in March 2022.

Key Points: 
  • Dr. Hack became CEO of VirTech Bio in March 2022.
  • VirTech Bio has previously raised seed funding of $6.7 MM which leverages $13.7 MM awarded in non-dilutive funding to date, primarily from the DoD.
  • The Florida Venture Summit is being held in Miami (Dec. 6 -7, 2022) and is billed as a premier event 'Where Innovation Meets Capital'.
  • For more information about VirTech Bio contact us at: [email protected] .

Valitor Announces Presentation on Novel Anti-VEGF Antibody Conjugate and Multivalent Polymer Technology Platform at Upcoming Ophthalmology Innovation Source (OIS) Summit

Retrieved on: 
Thursday, December 1, 2022

The presentation will review VLTR-557, an anti-VEGF therapy that is expected to provide effective therapy against wet age-related macular degeneration (AMD) with twice-yearly dosing based on preclinical findings.

Key Points: 
  • The presentation will review VLTR-557, an anti-VEGF therapy that is expected to provide effective therapy against wet age-related macular degeneration (AMD) with twice-yearly dosing based on preclinical findings.
  • Preclinical studies have demonstrated that VLTR-557 has an exceptional overall safety profile and does not leave residual depot materials within the eye.
  • VLTR-557 was created using the companys Multivalent Polymer (MVP) technology platform, which enables the development of novel macromolecular compounds through the use of biopolymers that can be engineered with multiple copies of bioactive molecules.
  • We are addressing this challenge with the development of our next generation anti-VEGF therapy, VLTR-557, and we look forward to keeping the community apprised of our progress as we begin IND-enabling studies.

ObsEva Announces Third Quarter 2022 Financial Results and Provides a Business Update

Retrieved on: 
Thursday, December 1, 2022

53 LR of the SIX Swiss Exchange

Key Points: 
  • 53 LR of the SIX Swiss Exchange
    GENEVA, Switzerland December 1, 2022 ObsEva SA (NASDAQ: OBSV; SIX: OBSN) (ObsEva or the Company), a biopharmaceutical company developing novel therapies for womens health, today reported financial results for the third quarter ended September 30, 2022 and provided a business update.
  • Financial Results for the Third Quarter Ended September 30, 2022
    ObsEva had cash and cash equivalents of $9.7 million at September 30, 2022 compared to $54.7 million at December 31, 2021.
  • The third quarter 2022 financial statements can be accessed in the financial reports section here of the Companys website, or directly here .
  • These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements.

Hillstream BioPharma Announces Development of Proprietary Targeted Biologics, Knob Quatrabodies™ (HSB-1940) against PD-1, by combining Quatramers™ with OmniAb’s Picobodies™, via a Collaboration Agreement, against Novel, Unreachable and Undruggable

Retrieved on: 
Thursday, December 1, 2022

BRIDGEWATER, N.J., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream”, the “Company”) today announced the development of proprietary targeted biologics, Knob Quatrabodies™ (HSB-1940) against PD-1. Hillstream signed separate collaboration agreements with a subsidiary of OmniAb, Inc. (Nasdaq: OABI) (“OmniAb”) and with Minotaur Therapeutics, Inc. (“Minotaur”) to advance Picobodies against novel, unreachable and undruggable epitopes in high-value validated targets starting with PD-1.

Key Points: 
  • Targeting PD-1 is a step toward enabling Hillstream to enter the rapidly growing Immuno-oncology (IO) therapeutics market with additional IO targets after PD-L1.
  • Alternative species, particularly camelids and bovines, provide a paradigm for antigen recognition through novel domains which form the antigen binding site.
  • However, for camelids, heavy chain antibodies bind antigen with only a single heavy chain variable region, in the absence of light chains.
  • At ~4-6 kDa, these are three times smaller than a camelid nanobody, and are the smallest known antibody fragment.